scholarly journals Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease

Blood ◽  
2013 ◽  
Vol 121 (12) ◽  
pp. 2340-2346 ◽  
Author(s):  
Yoshihiro Inamoto ◽  
Barry E. Storer ◽  
Stephanie J. Lee ◽  
Paul A. Carpenter ◽  
Brenda M. Sandmaier ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Systemic Treatment ◽  
Second Line ◽  
Relapse Free Survival ◽  
Treatment Change ◽  
Free Survival ◽  
Host Disease ◽  
Graft Versus Host ◽  
End Point ◽  
Key Points

Key Points Relapse-free survival without treatment change can form the basis of the primary end point in studies of chronic graft-versus-host disease. Steroid doses at the time of assessment should be taken into account in treatment studies of chronic graft-versus-host disease.

scholarly journals Validation of the Composite End Point of Graft-Versus-Host Disease-Free, Relapse-Free Survival

2016 ◽  
Vol 22 (3) ◽  
pp. S339-S340
Author(s):  
Kenji Motohashi ◽  
Masatsugu Tanaka ◽  
Jun Taguchi ◽  
Maki Hagihara ◽  
Kenji Matsumoto ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Host Disease ◽  
Graft Versus Host ◽  
End Point ◽  
Disease Free

scholarly journals Failure-free survival after initial systemic treatment of chronic graft-versus-host disease

Blood ◽  
2014 ◽  
Vol 124 (8) ◽  
pp. 1363-1371 ◽  
Author(s):  
Yoshihiro Inamoto ◽  
Mary E. D. Flowers ◽  
Brenda M. Sandmaier ◽  
Sahika Z. Aki ◽  
Paul A. Carpenter ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Initial Treatment ◽  
Systemic Treatment ◽  
Chronic Gvhd ◽  
Free Survival ◽  
Host Disease ◽  
Graft Versus Host ◽  
Key Points

Key Points Failure-free survival is a potentially useful, efficient, and robust basis for interpreting results of initial treatment of chronic GVHD.

scholarly journals Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation

Blood ◽  
2015 ◽  
Vol 125 (8) ◽  
pp. 1333-1338 ◽  
Author(s):  
Shernan G. Holtan ◽  
Todd E. DeFor ◽  
Aleksandr Lazaryan ◽  
Nelli Bejanyan ◽  
Mukta Arora ◽  
...  
Keyword(s):  
Cell Transplantation ◽  
Graft Versus Host Disease ◽  
Hematopoietic Cell Transplantation ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Graft Versus Host ◽  
End Point ◽  
Key Points ◽  
Matched Sibling ◽  
Disease Free

Key Points GRFS is a new composite end point useful for comparing HCT techniques and represents ideal post-HCT recovery. In our cohort of 907 allogeneic HCT recipients, 1-year GRFS was 31%, with best outcomes in recipients of marrow from matched sibling donors.

scholarly journals A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention

2021 ◽  
Vol 5 (13) ◽  
pp. 2740-2750
Author(s):  
Lia Perez ◽  
Hugo Fernandez ◽  
Mohamed Kharfan-Dabaja ◽  
Farhad Khimani ◽  
Brian Betts ◽  
...  
Keyword(s):  
Histone Deacetylase ◽  
Graft Versus Host Disease ◽  
Cumulative Incidence ◽  
Primary Study ◽  
Phase 2 ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Host Disease ◽  
Graft Versus Host ◽  
Phase 2 Trial

Abstract Immunomodulatory properties of histone deacetylase inhibitors represent a reasonable approach for acute graft-versus-host disease (aGVHD) prevention. We report a phase 2 trial evaluating panobinostat (PANO) administered over 26 weeks, starting on day −5 (5 mg orally 3 times a week) with tacrolimus initiated on day −3 plus sirolimus on day −1, with a median patient age of 58 years (range, 19-72 years) (n = 38). Donor source consisted of HLA 8/8–matched donors, related (n = 13) or unrelated (n = 25), using granulocyte colony-stimulating factor–stimulated peripheral blood stem cells. Myeloablative (n = 18) or reduced-intensity (n = 20) conditioning regimens were used for patients with acute myeloid leukemia (n = 17), myelodysplastic syndrome (n = 13), or other malignancies (n = 8). The cumulative incidence of aGVHD II-IV by day 100 was 18.4% (90% confidence interval [CI], 9.4% to 29.9%). Cumulative incidence of chronic GVHD at 1 year was 31.6% (90% CI, 19.5% to 44.3%). Adverse events related to PANO were thrombocytopenia (n = 5), leukopenia (n = 6), gastrointestinal toxicity (n = 3), rash (n = 4), renal failure/peripheral edema (n = 1), and periorbital edema (n = 1). At 1 year, overall survival was 89.5% (90% CI, 81.6% to 98.0%), relapse-free survival was 78.9% (90% CI, 68.8% to 90.6%), nonrelapse mortality was 2.6% (90% CI, 0.3% to 9.9%), and GVHD relapse-free survival was 60.5% (90% CI, 48.8% to 75.1%). PANO hits histone 3 as early as day 15 in CD8, CD4 and T regs. In conclusion, PANO combination met the primary study end point for aGVHD prevention and warrants further testing. This trial was registered at www.clinicaltrials.gov as #NCT02588339.

scholarly journals Current Graft-versus-Host Disease–Free, Relapse-Free Survival: A Dynamic Endpoint to Better Define Efficacy after Allogenic Transplant

2017 ◽  
Vol 23 (7) ◽  
pp. 1208-1214 ◽  
Author(s):  
Scott R. Solomon ◽  
Connie Sizemore ◽  
Xu Zhang ◽  
Michelle Ridgeway ◽  
Melhem Solh ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Host Disease ◽  
Graft Versus Host ◽  
Disease Free
Sign in / Sign up

Export Citation Format

Share Document